Replies to post #2929 on Galectin Therapeutics Inc. (GALT)

[gss2003]

Good point. Unless they get a great offer they may just try and do a partnership for the skin conditions to continue the studies and wait for the CX readout.

If the CX readout is poor they can just support their partner and also try for a partnership on I-O. Not as big as a score, but maybe the Melanoma and AD are worth $8 and then I-O another $5-10.

[gss2003]

Good point. Unless they get a great offer they may just try and do a partnership for the skin conditions to continue the studies and wait for the CX readout.

If the CX readout is poor they can just support their partner and also try for a partnership on I-O. Not as big as a score, but maybe the Melanoma and AD are worth $8 and then I-O another $5-10.

[biotech2010]

You really don't have a clue about this company.

There is no early data coming out on the CX trial (not trail) because the trial design doesn't include it. This is a double blind study, do you know what that means?

As for this being 'early', it is not early, it is near the end of the run for GALT without a successful CX trial. The company has been around for 15 years and the current management team for 7, that is long enough to prove something of merit.